{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte+Macrophage+Colony-Stimulating+Factor+%28GM-CSF%29&page=14", "query": { "intervention": "Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 537, "total_pages": 54, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte+Macrophage+Colony-Stimulating+Factor+%28GM-CSF%29&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte+Macrophage+Colony-Stimulating+Factor+%28GM-CSF%29&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T23:04:53.961Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00665002", "title": "Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "WT-1", "type": "BIOLOGICAL" }, { "name": "Montanide", "type": "DRUG" }, { "name": "Sargramostim (GM-CSF)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2008-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2015-02-27", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00665002" }, { "nct_id": "NCT00002070", "title": "Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cytomegalovirus Retinitis", "HIV Infections" ], "interventions": [ { "name": "Sargramostim", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Schering-Plough", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sherman Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002070" }, { "nct_id": "NCT00046930", "title": "Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "zosuquidar trihydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 449, "start_date": "2002-09-17", "completion_date": null, "has_results": true, "last_update_posted_date": "2023-07-05", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 91, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046930" }, { "nct_id": "NCT00003199", "title": "Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "Inflammatory Breast Cancer", "Male Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Stage IIIB Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "19 Years to 65 Years" }, "enrollment_count": 50, "start_date": "1997-11", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-07-12", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003199" }, { "nct_id": "NCT00488592", "title": "Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Acute Myeloid Leukemia (AML)", "Chronic Myeloid Leukemia (CML)" ], "interventions": [ { "name": "WT1:126-134", "type": "BIOLOGICAL" }, { "name": "PR1:169-177 Peptide", "type": "BIOLOGICAL" }, { "name": "GM-CSF (Sargramostim)", "type": "DRUG" }, { "name": "Montanide adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 10, "start_date": "2007-06", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2021-07-12", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488592" }, { "nct_id": "NCT00429416", "title": "Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "L-leucyl-L-leucine Methyl Ester (LLME)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)", "type": "BIOLOGICAL" }, { "name": "Hematopoietic stem cell transplantation (HSCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2004-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00429416" }, { "nct_id": "NCT00003727", "title": "Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 22, "start_date": "1999-03", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2019-11-04", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003727" }, { "nct_id": "NCT00002697", "title": "Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": "1995-09", "completion_date": "2003-06", "has_results": false, "last_update_posted_date": "2013-07-03", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002697" }, { "nct_id": "NCT00031733", "title": "Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" }, { "name": "alum adjuvant", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2002-02", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031733" }, { "nct_id": "NCT01341652", "title": "Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "pTVG-HP", "type": "BIOLOGICAL" }, { "name": "rhGM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 99, "start_date": "2011-05-23", "completion_date": "2020-06-30", "has_results": true, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-10-13T23:04:53.961Z", "location_count": 3, "location_summary": "San Francisco, California • Baltimore, Maryland • Madison, Wisconsin", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01341652" } ] }